MENU

Company news

The fifth anniversary of ImmuneOnco and the completion ceremony of the antibody drug research and development center were held successfully

Date:2020-08-05 Views:296

On July 31, 2020, the fifth anniversary of ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. and the completion ceremony of antibody drug R & D center were successfully held in building 47, Lane 908, Ziping road. ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. was founded by Dr. Tian Wenzhi in June 2015. Since then, ImmuneOnco has developed rapidly. In June 2020, ImmuneOnco antibody drug research and development center will be relocated to building 47, Lane 908, Ziping road. Meanwhile, Room 502, 1043 HaLei Road, China (Shanghai) pilot free trade zone, the original office address, is still running. Building 47, taken from building 7, Phase 4, Zhoupu medical Valley, corresponds to the target CD47 of ImmuneOnco products. Building 47 covers an area of 2700 square meters, covering the antibody drug R & D center and antibody pilot production platform.




Leaders and guests invited to attend the ceremony include: Mr. Tang Shiqing, vice chairman of the CPPCC Pudong New Area and director of Pudong Science and Technology Economic Commission; Mr. Li Xiaoliang, vice director of Pudong Science and Technology Economic Commission; Mr. Wang Kairong, vice general manager of Zhangjiang group, chairman of Zhangjiang biomedical base, Zhangjiang International Medical Park and Zhangjiang medical equipment base; Ms. Lou Qi, vice chief economist of Zhangjiang group and development of Zhangjiang biomedical base.  Mr. Xia duo, general manager of Zhangjiang international medical park; Mr. Liu Gang, vice general manager of Zhangjiang biomedical base and Secretary General of Biological Industry Association of Pudong New Area;  Mr. Qiao Yi, general manager of Shanghai International Medical Park Joint Development Co., Ltd.; and other leaders, shareholders, industry colleagues, lawyers and financial circles.




Dr. Tian Wenzhi, chairman and general manager of the company, delivered a welcome speech on the spot, thanking the guests who came to the launching meeting of ImmuneOnco during their busy schedule, the colleagues in the industry and people who care and support the vigorous development of ImmuneOnco. He reviewed the development process of the company, shared the the achievements of the company since its establishment, and solemnly introduced the senior management team of the company.



"Since its establishment in 2015, ImmuneOnco has adhered to the road of independent research and development and independent intellectual property rights of original new drugs. The company has developed rapidly. At present, the original new drugs IMM01 and IMM0306 are in clinical trial research. The IMM2510 project has been submitted to pre-IND, and several other projects are in the preclinical research stage, and will gradually enter the clinical trial stage. Among them, IMM01 project perfectly solved the pain points of CD47 target research drugs, and the project was promoted rapidly; at the same time, there was no report on clinical trial research of other double target drugs such as IMM0306. " Dr. Tian Wenzhi, founder and chairman of ImmuneOnco, said: "it is a hard, exciting and maddening thing to do new drug research and development. In the past five years, although we have experienced hardships, we have bravely survived. We have a clear goal and a firm will. As always, we will work hard and march forward to the dawn with our heads held high.




Mr. Tang Shiqing, vice chairman of the CPPCC Pudong New Area and director of Pudong Science and Technology Economic Commission, and Mr. Yu Xiaoyong, general manager of Shanghai ZhangkeLingyi capital center (limited partnership), and other guests delivered wonderful speeches.



About ImmuneOnco

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. was founded in June 2015 and registered in Zhangjiang High Tech Park, Shanghai. The company is mainly committed to the development and research of tumor immunotherapy products, including bispecific antibodies, new recombinant proteins, and car-nk cell therapy. ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. was founded in June 2015 and registered in Zhangjiang High Tech Park, Shanghai. The company's first product, IMM01, and its second product, IMM0306, are in Phase I clinical trial study. Several other double target specific protein drugs are in preclinical research stage.


Contact us

Address: Room 502, 1043 HaLei Road, Pudong

New Area, Shanghai, China

Building 7, Lane 908, Ziping Road, Pudong

New Area, Shanghai, China

Tel. + 86 21 5835 6573

website: www.immuneonco.com